Diabetes treatment is constantly advancing, with new therapeutic options developing to improve patient outcomes. Recent investigations have focused on GLP-1 and GIP receptor agonists, a category of drugs that mimic the actions of naturally occurring hormones involved in bloodglucose regulation. These novel agents demonstrate promising results in ma

Retaglutide and tirzepatide represent innovative class of medications known as dual GLP-1 and GIP agonists. These agents regulate both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), two hormones that perform a crucial role in regulating blood sugar levels. In individuals with type 2 diabetes, these hormones